Your session is about to expire
← Back to Search
CAR T-cell Therapy
GDX012 Suspension for IV Infusion for Acute Myeloid Leukemia
Phase 1
Waitlist Available
Research Sponsored by GammaDelta Therapeutics Limited
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 1 year
Awards & highlights
Study Summary
This trial will test the safety and effectiveness of GDX012 in people with leukemia who have a positive MRD.
Eligible Conditions
- Acute Myeloid Leukemia
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ up to 1 year
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 1 year
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Establish the maximum tolerated dose (MTD) of GDX012
Incidence of dose limiting toxicities (DLTs)
Incidence of treatment emergent adverse events (AEs) and serious adverse events (SAEs)
+1 moreSecondary outcome measures
Evaluate the antileukemic activity of GDX012
Trial Design
1Treatment groups
Experimental Treatment
Group I: GDX012 Suspension for IV InfusionExperimental Treatment1 Intervention
Allogeneic cell therapy that is enriched for Vδ1+ γδ T cells
Find a Location
Who is running the clinical trial?
GammaDelta Therapeutics LimitedLead Sponsor
Michael Koslowski, MDStudy DirectorGammaDelta Therapeutics Limited
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Share this study with friends
Copy Link
Messenger